The short version of human growth hormone fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-25. Anything still debated is marked as such rather than presented as settled.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Caldwell, Donald and Richard Muller. The Luftwaffe over Germany – Defense of the Reich. St. Paul, Minnesota: Greenhill books, MBI Publishing, 2007. ISBN 978-185367-712-0. Carson, Leonard "Kit." Pursue & Destroy. Granada Hills, California: Sentry Books Inc., 1978. ISBN 0-913194-05-0. Carter, Dustin W. and Birch J. Matthews.Mustang: The Racing Thoroughbred. West Chester, Pennsylvania: Schiffer Publishing Company, 1992. ISBN 978-0-88740-391-0. Cleaver, Tom (April–July 1982). "Return of the Razorbacks". Air Enthusiast. No. 18. pp. 26–31. ISSN 0143-5450. Craven, Wesley; Cate, James (1949). The Army Air Forces in World War II, Volume Two: Europe, Torch to Pointblank, August 1942 to December 1943. Chicago: University of Chicago. Darling, Kev. P-51 Mustang (Combat Legend). Shrewsbury, UK: Airlife, 2002. ISBN 1-84037-357-1. Davis, Larry. P-51 Mustang. Carrollton, Texas: Squadron/Signal Publications, Inc., 1995. ISBN 0-89747-350-7. Dean, Francis H. America's Hundred Thousand. Atglen, Pennsylvania: Schiffer Publishing Ltd., 1997. ISBN 0-7643-0072-5. Delve, Ken. The Mustang Story. London: Cassell & Co., 1999. ISBN 1-85409-259-6. Delve, Ken. The Source Book of the RAF. Shrewsbury, Shropshire, UK: Airlife Publishing, 1994. ISBN 1-85310-451-5. Dienst, John and Dan Hagedorn. North American F-51 Mustangs in Latin American Air Force Service. London: Aerofax, 1985. ISBN 0-942548-33-7. Donald, David, ed. Encyclopedia of World Aircraft. Etobicoke, Ontario: Prospero, 1997. ISBN 1-85605-375-X. Dorr, Robert F. P-51 Mustang (Warbird History). St.
=== Phenol–chloroform extraction === The basic principle of the phenol-chloroform extraction is that DNA and RNA are relatively insoluble in phenol and chloroform, while other cellular components are relatively soluble in these solvents. The addition of a phenol/chloroform mixture will dissolve protein and lipid contaminants, leaving the nucleic acids in the aqueous phase. It also denatures proteins, like DNase, which is especially important if the plasmids are to be used for enzyme digestion. Otherwise, smearing may occur in enzyme restricted form of plasmid DNA.
Aesculin (C21H24O13), occurring in horse-chestnut and California buckeye, and daphnin, occurring in Daphne alpina, are isomeric; the former hydrolyzes to glucose and aesculetin (C9H6O4 — 6,7-dihydroxycoumarin), the latter to glucose and daphnetin (7,8-dihydroxycoumarin). Fraxin, occurring in Fraxinus excelsior, hydrolyzes to glucose and fraxetin (also known as 7,8-dihydroxy-6-methoxycoumarin) Flavone or benzo-7-pyrone derivatives are numerous; in many cases they (or the non-sugar part of the molecule) are vegetable dyes. Rhamnetin, a splitting product of the glucosides of Rhamnus, is monomethyl quercetin; fisetin, from Rhus cotinus, is monoxyquercetin; chrysin is phenyl-dihydroxybenzopyrone. Saponarin, a glucoside found in Saponaria officinalis, is a related compound. Strophanthin is the name given to two different compounds, g-strophanthin (ouabain) obtained from Strophanthus gratus and k-strophanthin from Stroph. kombé.
== Critical reception == After the airing of the second season, many have categorized Blue Ridge as a sleeper hit. The series began on INSP only, before streaming providers began to air the series. Pluto TV, Amazon Prime Video and Roku have all seen the show rise into their Top 10 most watched programs, more so with the second season. On Amazon, the series at times traded places with the blockbuster TV show, Reacher. The series has received steady reviews on IMDb with an overall rating of 6.6. Positive reviewers praise it as entertaining, family-friendly viewing built around a single father raising his daughter alongside his ex-wife's family, and describe him as dealing with some PTSD. On Amazon, it has received a 4.4 out of 5 rating.
Sources: en.wikipedia.org
The situation has also reignited a debate over gain-of-function research, although the intense political rhetoric surrounding the issue has threatened to sideline serious inquiry over policy in this domain.
== Early life and military service == Jerome Kalman Sherman was born in 1925 in Brooklyn, New York, to Murray and Beatrice Sherman, a sailmaker and Navy Yard worker. After graduating from Erasmus Hall High School early, he enrolled at Brooklyn College at the age of 16, but after three semesters put his studies on hold to enlist in the military during World War II. At age 17, in 1943, Sherman joined the U.S. Navy as a seaman and earned a commission at Notre Dame. He then served in the Pacific Theater as an anti-submarine officer until 1945, learning of the Japanese surrender on his 20th birthday. Subsequently he served in occupied Japan as part of the first naval line officer to enter Nagasaki, left the Navy as a lieutenant commander.
=== Average molar mass of mixtures === An average molar mass may be defined for mixtures of substances. This is particularly important in polymer science, where there is usually a molar mass distribution of non-uniform polymers so that different polymer molecules contain different numbers of monomer units. The average molar mass of mixtures
Sources: en.wikipedia.org
At rates of use at that time (72 million SCM per year in the U.S.; see pie chart below) this would have been enough helium for about 58 years of U.S. use, and less than this (perhaps 80% of the time) at world use rates, although factors in saving and processing impact effective reserve numbers. Helium is commercially available in either liquid or gaseous form. As a liquid, it can be supplied in small insulated containers called dewars which hold as much as one cubic metre (1,000 L) of helium, or in large ISO containers, which have nominal capacities as large as 42 m3 (around 11,000 U.S. gallons). In gaseous form, small quantities of helium are supplied in high-pressure cylinders holding as much as 8 m3 (approximately .282 standard cubic feet), while large quantities of high-pressure gas are supplied in tube trailers, which have capacities of as much as 4,860 m3 (approx. 172,000 standard cubic feet).
An X-ray examination can be used to detect changes in the size, density and position of the kidneys as well as some urinary stones (struvite and calcium oxalate stones are "radiopaque") and soft tissue calcifications. In severely emaciated cats or fluid accumulations in the retroperitoneal space, however, the kidney can only be visualized to a limited extent on the X-ray image due to the resulting reduction in contrast. Excretory urography, in which a radiopaque contrast medium (e.g. Iopamidol, Iohexol) is injected into the bloodstream and its excretion via the kidneys is recorded radiographically. This makes it possible to detect circulatory disorders, dysfunctions of the renal corpuscles and obstructions of the outflow pathways.
Navy shore bombardment and submarine operations. The Japanese increased their garrison in the north Kurils from 8,000 in 1943 to 41,000 in 1944 and maintained more than 400 aircraft in the Kurils and Hokkaido area in anticipation that the Americans might invade from Alaska.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.